CORD-19:5b86e6307a43623963d73738a991a2f37e91488b / 213315-213526 JSONTXT

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T122","span":{"begin":0,"end":211},"obj":"Sentence"}],"text":"Compromised resistance, perhaps associated with neoplasia, endogenous or exogenous steroids, lympholytic viral disease, and altered gastrointestinal flora due to antiobiotic therapy, may further promote mycosis."}

{"project":"CORD-19-Sentences","denotations":[{"id":"T93365","span":{"begin":0,"end":211},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Compromised resistance, perhaps associated with neoplasia, endogenous or exogenous steroids, lympholytic viral disease, and altered gastrointestinal flora due to antiobiotic therapy, may further promote mycosis."}

{"project":"Epistemic_Statements","denotations":[{"id":"T726","span":{"begin":0,"end":211},"obj":"Epistemic_statement"}],"text":"Compromised resistance, perhaps associated with neoplasia, endogenous or exogenous steroids, lympholytic viral disease, and altered gastrointestinal flora due to antiobiotic therapy, may further promote mycosis."}

{"project":"CORD-19-PD-HP","denotations":[{"id":"T731","span":{"begin":48,"end":57},"obj":"Phenotype"}],"attributes":[{"id":"A731","pred":"hp_id","subj":"T731","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"Compromised resistance, perhaps associated with neoplasia, endogenous or exogenous steroids, lympholytic viral disease, and altered gastrointestinal flora due to antiobiotic therapy, may further promote mycosis."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T1205","span":{"begin":48,"end":57},"obj":"Disease"},{"id":"T1206","span":{"begin":105,"end":118},"obj":"Disease"},{"id":"T1207","span":{"begin":203,"end":210},"obj":"Disease"},{"id":"T60966","span":{"begin":48,"end":57},"obj":"Disease"},{"id":"T18517","span":{"begin":105,"end":118},"obj":"Disease"},{"id":"T69710","span":{"begin":203,"end":210},"obj":"Disease"}],"attributes":[{"id":"A1205","pred":"mondo_id","subj":"T1205","obj":"http://purl.obolibrary.org/obo/MONDO_0005070"},{"id":"A1206","pred":"mondo_id","subj":"T1206","obj":"http://purl.obolibrary.org/obo/MONDO_0005108"},{"id":"A1207","pred":"mondo_id","subj":"T1207","obj":"http://purl.obolibrary.org/obo/MONDO_0002041"},{"id":"A22270","pred":"mondo_id","subj":"T60966","obj":"http://purl.obolibrary.org/obo/MONDO_0005070"},{"id":"A73998","pred":"mondo_id","subj":"T18517","obj":"http://purl.obolibrary.org/obo/MONDO_0005108"},{"id":"A20081","pred":"mondo_id","subj":"T69710","obj":"http://purl.obolibrary.org/obo/MONDO_0002041"}],"text":"Compromised resistance, perhaps associated with neoplasia, endogenous or exogenous steroids, lympholytic viral disease, and altered gastrointestinal flora due to antiobiotic therapy, may further promote mycosis."}